Bitwise Bitcoin ETF Common Shares of Beneficial Interest (ARCA: BITB)

Dernières nouvelles pour Bitwise Bitcoin ETF Common Shares of Beneficial Interest (ARCA:BITB)

In seeking to achieve its investment objective, the Trust will hold bitcoin and establish its net asset value (NAV) with reference to the CME CF Bitcoin Reference Rate - New York Variant (BRRNY)

Bitwise Bitcoin ETF

Bitwise Bitcoin ETF Common Shares of Beneficial Interest

Bitball Treasure

Keybanc analyst Ken Newman downgrades Symbotic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYM#NASDAQ">SYM</a>) from Overweight to Sector Weight.

News

Downgrades

Analyst Ratings

Keybanc Downgrades Symbotic to Sector Weight

JPMorgan Chase (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JPM#NYSE">JPM</a>) CEO <a href="https://www.benzinga.com/general/politics/24/10/41192406/jamie-dimon-rejects-trump-endorsement-claim-casting-doubt-on-treasury-rumors">Jamie Dimon</a> is optimistic about President-elect Donald Trump's plans to cut back on regulations and he says <a href="https://www.benzinga.com/24/11/42029764/global-banks-jp-morgan-goldman-sachs-add-to-bitcoin-ethere-etf-positions-in-q3-morgan-stanley-increases-microstrategy-stake-to-16b">Wall Street bankers</a> are thrilled. In a recent talk during the APEC CEO Summit in Peru, Dimon said that the industry is <a href="https://www.benzinga.com/content/42151857/top-3-financial-stocks-set-to-gain-from-looser-regulations">hopeful that Trump's win will result in less red tape</a>, allowing banks to do more of what they do best: lend money.
Don't Miss:
<ul>
<li>‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. <a href="https://www.benzinga.com/money/mode-mobile-2">You can invest TODAY for just $0.26/share with a $1000 minimum.</a></li>
<li>If there was a new fund backed by Jeff Bezos offering a <a href="https://www.benzinga.com/money/arrived-private-credit-fund">7-9% target yield with monthly dividends would you invest in it</a>?</li>
</ul>
"A lot of bankers, they're like dancing in the street because they've had successive years and years of regulations, a lot of which stymied credit," Dimon said. His point is that all the rules implemented over the past years have made it harder for banks to lend money, impacting businesses and the overall economy.
<h2 class="wp-block-heading">Regulations That Hold Banks Back</h2>
Dimon explained that banks in the U.S. used to lend out $100 for every $100 in deposits they held. But now, with all the restrictions, they only lend about $65 for every $100 in deposits. He feels that tougher laws have made it difficult for banks to perform their functions and that reducing these rules could help.
"If that's what you want, if for some reason the regulators think they're geniuses and that's the best way to run the banking system, so be it," Dimon said. He also pointed out that regulators likely didn't anticipate the negative effect that their rules would have on credit and lending.
See Also: The global games market is projected to generate $272B by the end of the year —<a href="https://www.benzinga.com/money/gameflip"> for $0.55/share, this VC-backed startup with a 7M+ userbase gives investors easy access to this asset market.</a>
<h2 class="wp-block-heading">Why Banking Regulations Are Important</h2>
Banking regulations were put in place primarily to ensure the stability and safety of the financial system, protect consumers and prevent reckless behavior that could lead to economic crises. After the 2008 financial crisis, regulations were tightened to reduce the risks banks could take with their lending and investment practices. These rules are crucial in maintaining trust in the banking sector, preventing <a href="https://www.benzinga.com/personal-finance/24/11/41949050/bill-gates-warned-the-u-s-will-experience-another-2008-style-financial-crisis-he-cant-predict-when-but-says-this-is-a-certainty">another financial meltdown</a> and ensuring that banks operate responsibly without jeopardizing the broader economy.
Trending: Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing —<a href="https://www.benzinga.com/money/boxabl"> you can become an investor for $0.80 per share today.</a>
<h2 class="wp-block-heading">Hope for Change</h2>
Dimon applauded Trump's intentions to streamline government and reduce the regulatory burden, highlighting that the right changes could help bankers and many industries. "You could talk to any industry and they'll give you examples of regulations that could be reduced to make it easier for them to do business while keeping the country safe," Dimon added.
Trump has already started putting together a team to tackle these issues. He recently announced that Tesla CEO Elon Musk and pharma entrepreneur Vivek Ramaswamy would lead the Department of Government Efficiency (DOGE), a new task force focused on <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42035165/coinbase-ceo-brian-armstrong-says-doge-department-is-a-once-in-a-lifetime-opprtunity-advocates-abolishing-individual-income-tax">cutting down excessive regulations</a>. The goal is to reduce wasteful government spending and restructure federal agencies.
Read Next:
<ul>
<li>Inspired by Uber and Airbnb &#8211; Deloitte's fastest-growing software company is transforming 7 billion smartphones into income-generating assets &#8211; <a href="https://www.benzinga.com/money/mode-mobile-2">with $1,000 you can invest at just $0.26/share!</a></li>
<li>This Jeff Bezos-backed startup will allow you to <a href="https://www.benzinga.com/money/bezos-landlord-100-dollars">become a landlord in just 10 minutes, with minimum investments as low as $100 for properties like the Byer House from Stranger Things.</a></li>
</ul>

Startups

Jamie Dimon Says Trump's Plans To Loosen Regulations Have Bankers 'Dancing In The Street'

When the Drug Enforcement Administration <a href="https://www.benzinga.com/markets/cannabis/23/07/33156524/dea-turns-50-unveiling-the-ineffectiveness-of-the-ongoing-war-on-drugs-now-what">marked its 50th anniversary </a>last year, it had spent over $1 trillion partly to enforce Richard Nixon's 1970 Controlled Substances Act, the cornerstone of his <a href="https://www.benzinga.com/topic/war-on-drugs">War on Drugs</a>, which is widely viewed as a failure.
Now, doesn't this sound like the type of government agency President-elect Donald Trump's new Department of Government Efficiency&nbsp;(DOGE) might want to take a closer look at? The DOGE <a href="https://www.benzinga.com/news/global/24/11/41927289/trump-appoints-elon-musk-and-vivek-ramaswamy-to-lead-doge-targeting-bureaucracy-and-65-trillion-federal-spending-we-will-not-go-gently">initiative</a>, co-led by Elon Musk and Vivek Ramaswamy, is meant to focus on dismantling bureaucracy, reducing regulations and cutting wasteful expenditures.
Both Musk and Ramaswamy have publicly acknowledged they are in favor of legalizing cannabis. In fact, so has <a href="https://www.benzinga.com/markets/cannabis/24/10/41370277/donald-trump-appears-in-florida-cannabis-legalization-campaign-ad-discussing-his-support-for-leg">Trump for that matter</a>.
Read Also: <a href="https://www.benzinga.com/24/11/42173101/dea-denies-allegations-of-unlawful-talks-with-anti-marijuana-group">DEA Denies Allegations Of Colluding With Anti-Marijuana Group While Involved In Cannabis Rescheduling Process</a>
Meanwhile, the DEA, health officials and interested cannabis advocates are taking part in at times contentious <a href="https://www.benzinga.com/topic/cannabis-rescheduling" target="_blank" rel="noreferrer noopener">marijuana rescheduling pre-hearings</a> this week with the formal meeting scheduled to begin Dec. 2. The hearings stem from <a href="https://www.benzinga.com/markets/cannabis/23/08/34126690/hhs-secretary-confirms-it-is-recommending-cannabis-be-rescheduled-per-bidens-directive">President Joe Biden&#8216;s August 2023 directive</a> to downgrade the status of cannabis in the Controlled Substances Act (CSA).
The CSA, signed by Nixon in 1970, classifies drugs and sets criminal penalties for their use, possession and distribution.
While he was at it, Nixon launched the War on Drugs, which actually turned out to be an assault on anti-Vietnam-war protestors and the Black community.
How do we know that, you might ask? Someone who helped Nixon pull the project together named names.
<h2 class="wp-block-heading">John Ehrlichman Spills The Beans</h2>
"The Nixon campaign in 1968, and the Nixon White House after that, had two enemies: the antiwar left and black people," Nixon's top adviser, John Ehrlichman told the writer Dan Baum in a 1994 interview that Baum later used in a Harper's Magazine <a href="https://harpers.org/archive/2016/04/legalize-it-all/">article</a>. 
&#8220;We knew we couldn't make it illegal to be either against the war or blacks, but by getting the public to associate the hippies with marijuana and blacks with heroin, and then criminalizing both heavily, we could disrupt those communities,&#8221; said Ehrlichman who died in 1999. 
&#8220;We could arrest their leaders, raid their homes, break up their meetings, and vilify them night after night on the evening news. Did we know we were lying about the drugs? Of course, we did."
<h2 class="wp-block-heading">DEA&#8217;s Changing Attitude </h2>
The DEA&#8217;s focus, having shifted from its strident anti-marijuana goals, now includes among other things <a href="https://www.benzinga.com/markets/cannabis/24/01/36707665/dea-seizes-largest-amount-of-fentanyl-in-its-history-386m-lethal-doses-enough-to-kill-every-amer">stemming the flow </a>of fentanyl into the U.S.
Nevertheless, Musk and Ramaswamy, with scientific research confirming the health benefits of cannabis and the fact that it&#8217;s legal in some form in 40 states, it might be the moment to cut back on an agency that <a href="https://www.gao.gov/products/gao-23-105508">continues to spend</a> billions on punitive actions against a substance both you and <a href="https://www.benzinga.com/markets/cannabis/24/03/37964845/9-out-of-10-americans-support-some-form-of-legal-cannabis-pew-research-center-finds">nearly 80% of the U.S. population</a> either partake in or believe should be legal. What do you say, gentlemen?
Now Read:
<ul>
<li><a href="https://www.benzinga.com/24/11/42169153/dea-judge-blocks-researchers-motion-in-cannabis-rescheduling-case">DEA Judge Blocks Researcher&#8217;s Motion In Cannabis Rescheduling Case</a></li>
</ul>
Photo: Shutterstock.

Cannabis

Government

Politics

Legal

Opinion

Exclusives

Elon Musk, Vivek Ramaswamy: Here's An Agency You Might Want To Cut Back On And Save $40 Billion A Year

TD Cowen analyst Daniel Bergman maintains MetLife (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MET#NYSE">MET</a>) with a Buy and raises the price target from $97 to $99.

Price Target

TD Cowen Maintains Buy on MetLife, Raises Price Target to $99

Amphenol's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APH#NYSE">APH</a>) short percent of float has risen 29.81% since its last report. The company recently reported that it has 14.23 million shares sold short, which is 1.35% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.06 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Amphenol Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732725921_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Amphenol has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Amphenol's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Amphenol's peer group average for short interest as a percentage of float is 3.90%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Trading Ideas

Looking Into Amphenol's Recent Short Interest

Select Medical Hldgs's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SEM#NYSE">SEM</a>) short percent of float has fallen 11.22% since its last report. The company recently reported that it has 1.79 million shares sold short, which is 2.69% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.15 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Select Medical Hldgs Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732725917_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Select Medical Hldgs has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Select Medical Hldgs's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Select Medical Hldgs's peer group average for short interest as a percentage of float is 4.11%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

(SEM) - Analyzing Select Medical Hldgs's Short Interest

Summit Materials's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SUM#NYSE">SUM</a>) short percent of float has fallen 14.2% since its last report. The company recently reported that it has 3.19 million shares sold short, which is 2.96% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.07 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Summit Materials Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732725911_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Summit Materials has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Summit Materials's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Summit Materials's peer group average for short interest as a percentage of float is 2.28%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Looking Into Summit Materials's Recent Short Interest

Raymond James analyst Sean McCutcheon initiates coverage on enGene Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENGN#NASDAQ">ENGN</a>) with a Outperform rating and announces Price Target of $23.

Initiation

ENGN

Raymond James Initiates Coverage On enGene Holdings with Outperform Rating, Announces Price Target of $23

Following a private artificial intelligence discussion at Capitol Hill last year,&nbsp;Palantir Technologies Inc&nbsp;(NYSE:&nbsp;<a href="https://www.benzinga.com/stock/pltr#NYSE">PLTR</a>) CEO&nbsp;Alex Karp&nbsp;publicly discussed the&nbsp;<a href="https://www.benzinga.com/news/23/09/34505513/leading-ai-companies-get-serious-about-managing-risks">potential dangers of AI</a>.
What Happened:&nbsp;In a September 2023 interview on CNBC&#8217;s &#8220;Squawk On The Street,&#8221; Karp called on other tech companies to work with the government on their AI initiatives.
&#8220;The Silicon Valley motto has been &#8216;I get rich, you get nothing,&#8217; and they obviously often have extended that to the U.S. government,&#8221; Karp said.&nbsp;
Palantir was embarrassing other people in AI when it came to working with the government, Karp said slyly. The company was involved in talking with legislators and helping them understand that way too few dollars are <a href="https://www.benzinga.com/topic/ai">being spent on AI.</a>
The Palantir chief noted&nbsp;Palantir was one of the only companies since the 1950s that has produced government products which&nbsp;are commercially in high demand.
The overarching discussion at a recent closed meeting with senators involved figuring out how to advance AI while simultaneously mitigating risks, Karp explained.&nbsp;
&#8220;What happens if&nbsp;generative AI becomes so powerful that in fact, it is a risk to humankind?&nbsp;That is a real issue,&#8221; he said.
Furthermore, we [the U.S.] must make sure our adversaries, namely Russia and China, don&#8217;t develop tools that are vastly superior to ours and change the world order, he added.&nbsp;
Karp suggested&nbsp;the discussions were very productive. It&#8217;s easier to get people to &#8220;go naked&#8221; in private because you can say what you believe without facing public scrutiny, he said.&nbsp;
&#8220;There was a super heterogeneous group of people there from union leaders to tech leaders. Among tech leaders you have kind of more corporate-y people, then you have the freak show,&#8221; Karp said referring to himself.&nbsp;
Check This Out: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/11/42200429/elon-musk-is-responsible-for-palantir-stock-rally-jim-cramer-says">Elon Musk Is Responsible For Palantir Stock Rally, Jim Cramer Says</a>
Why It Matters:&nbsp;Karp sat next to&nbsp;Tesla Inc&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) CEO&nbsp;Elon Musk&nbsp;at the&nbsp;closed-door U.S. Senate discussion&nbsp;on&nbsp;regulating AI.
He told CNBC that he and Musk discussed the future of AI and its potential risks to humanity. He was unwilling to share Musk&#8217;s comments, but he shared what he told Musk.&nbsp;
&#8220;There&#8217;s&nbsp;those that think AI is safe and&nbsp;those that think it&#8217;s dangerous. I&#8217;m in the third camp which is it is dangerous and if we don&#8217;t actually&nbsp;work on it, our adversaries will and we will lose all of our human rights — that was my position,&#8221; Karp said.&nbsp;
In an excerpt from Musk&#8217;s biography, author&nbsp;Walter Isaacson&nbsp;revealed that in a&nbsp;<a href="https://www.benzinga.com/news/23/09/34328862/inside-elon-musks-secret-life-biography-reveals-ai-worries-photo-of-twins-ignites-family-drama">secretive meeting between him and the billionaire</a>,&nbsp;Musk pondered what could be done to make AI safe, including actions that could be taken to &#8220;assure that human consciousness survives.&#8221;
&#8220;Musk somberly speculated about the window of opportunity for building a sustainable human colony on Mars before an AI apocalypse destroyed earthly civilization,&#8221; Isaacson wrote.&nbsp;
The Tesla CEO&nbsp;<a href="https://www.benzinga.com/news/23/07/33202228/elon-musk-quietly-launches-xai-amid-bid-to-decode-universe">launched X.ai</a> with the goal of understanding the &#8220;true nature of the universe.&#8221; Musk has openly&nbsp;<a href="https://www.benzinga.com/news/23/09/34659019/elon-musks-caution-for-openai-googles-gemini-ai-musk-and-zuckerbergs-truce-top-ai-stories-this-week">expressed his concerns</a>&nbsp;about the future of AI several times, including in various posts on the X platform.&nbsp;
Karp said that he shares the same opinions both privately and publicly.
&#8220;There&#8217;s a real risk here, but the upside is that America will outperform all other Western countries because we produce the technology, we have&nbsp;legal structures that allow us to implement it and we have the best talent and we are the most innovative,&#8221; Karp said.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/24/11/42179988/dan-ives-defends-75-palantir-target-amid-ai-revolution-and-revenue-surge-haters-will-continue-to-hate">Dan Ives Defends $75 Palantir Target Amid AI Revolution And Revenue Surge: &#8216;Haters Will Continue To Hate&#8217;&nbsp;</a></li>
</ul>
Photo: <a href="https://www.flickr.com/photos/worldeconomicforum/" target="_blank" rel="noreferrer noopener">World Economic Forum</a> on Flickr and Shutterstock.
Some elements of this story were previously reported by Benzinga and it has been updated.

Tech

General

PLTR

TSLA

'It Is Dangerous': Palantir Chief Alex Karp, Elon Musk Sound Alarm On AI — Is Anyone Listening?

Piper Sandler analyst Crispin Love maintains Virtus Inv (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VRTS#NYSE">VRTS</a>) with a Overweight and raises the price target from $264 to $274.

VRTS

Piper Sandler Maintains Overweight on Virtus Inv, Raises Price Target to $274

VCIG

VCI Global Shares Halted On Circuit Breaker To The Upside, Stock Now Up 269.3%

Greenway Greenhouse Cannabis Corporation (CSE:<a class="ticker" href="https://www.benzinga.com/stock/GWAY#CSE">GWAY</a>) (OTCQB:<a class="ticker" href="https://www.benzinga.com/stock/GWAYF#OTCQB">GWAYF</a>) reported on Wednesday its second-quarter interim financial statements for the three months ended Sept. 30, 2024.
The Canadian cultivator of high-quality greenhouse cannabis reported a 52% year-over-year increase in revenue to CA$1.8 million ($1.3 million). Moreover, for the first half of the fiscal year, Greenway&#8217;s net revenue increased by 78% compared to the same period in 2023.
CEO Jamie D&#8217;Alimonte highlighted the company&#8217;s revenue growth, product performance and ongoing commitment to quality cannabis production in a press release issued Wednesday.
&#8220;We have also seen our MillRite brand maintain itself as the #2 ranked pre-roll in its size category, while achieving the #2 Indica and Sativa pre-roll in the size category over the same time," D&#8217;Alimonte said. "Quarter over quarter, we have seen the total number of units sold increase by over 70%. Our plan to deliver high-quality, affordable products to Ontario users is working. I look forward to introducing additional SKUs in the New Year.&#8221; Despite reporting a net loss, the company emphasized its strong market position and ongoing improvements as drivers of long-term growth.
Read Also: <a href="https://www.benzinga.com/markets/cannabis/24/08/40604376/greenway-cannabis-co-doubles-q1-net-revenue-yoy-highest-adjusted-ebitda-results-to-date">Greenway Cannabis Co. Doubles Q1 Net Revenue YoY, Highest Adjusted EBITDA Results To Date</a>
<h3 class="wp-block-heading">Q2 Financial Highlights</h3>
<ul>
<li>Gross loss of CA$88,955, down from a gross profit of CA$80,972 in the prior year, reflecting increased production costs and pricing pressures.</li>
<li>Loss and comprehensive loss totaled roughly CA$1 million, up from CA$662,213 loss and comprehensive loss in the same quarter of last year.</li>
<li>Net cash provided by operating activities of CA$743,731 compared to cash used of CA$664,171 in the same quarter of the previous year.</li>
<li>Adjusted EBITDA came in negative at CA$253,010, compared to an adjusted EBITDA loss of CA$ $112,221 in the prior year's period.</li>
</ul>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/07/40047803/greenways-full-year-net-loss-widens-sees-rebound-in-q4-as-revenue-increases-9-yoy">Greenway&#8217;s Full-Year Net Loss Widens, Sees Rebound In Q4 As Revenue Increases 9% YoY</a></li>
</ul>

Earnings

CSE:GWAY

GWAYF

Greenway Greenhouse Cannabis Sees 52% YoY Growth In Q2 Revenue Amid Rising Losses And Cost Challenges

Dell Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DELL#NYSE">DELL</a>) shares are trading lower after the company reported worse-than-expected 2025 fiscal-year third-quarter sales results on Tuesday <a href="https://www.benzinga.com//node/42201885">after the bell</a>.
The Details: Dell stock dropped approximately 6.5% following its earnings report on Tuesday and continues to decline on Wednesday morning. The earnings report included sales of $24.37 billion, missing analyst estimates of $24.65 billion but representing a 10% year-over-year increase.
The company broke down its sales further, reporting $11.4 billion from its Infrastructure Solutions Group (ISG) and $12.1 billion from its Client Services Group (CSG). In addition, the company reported adjusted earnings per share of $2.15, beating analyst estimates of $2.05.
&#8220;We continued to build on our AI leadership and momentum, delivering combined ISG and CSG revenue of&nbsp;$23.5 billion, up&nbsp;13%&nbsp;year over year,&#8221; said&nbsp;Yvonne McGill, CFO of Dell. 
&#8220;Our continued focus on profitability resulted in EPS growth that outpaced revenue growth, and we again delivered strong cash performance.&#8221;
On a note, Goldman Sachs remained positive about Dell&#8217;s long-term outlook, citing strong AI server demand and opportunities from a delayed PC refresh cycle expected to materialize in 2025. Goldman highlighted strong AI orders of $3.6 billion, contributing to a $4.5 billion backlog in AI servers.
However, Goldman Sachs acknowledged some short-term challenges, including weaker demand for PCs and a delayed recovery in the PC refresh cycle. The firm also noted that while AI server demand remains strong, Blackwell server shipments could face headwinds from component availability, potentially impacting next quarter's results.
Related Link: <a href="https://www.benzinga.com/insights/options/24/11/42217772/a-closer-look-at-gamestops-options-market-dynamics">A Closer Look at GameStop&#8217;s Options Market Dynamics</a>
DELL Price Action: At the time of publication, Dell stock is trading 12.9% lower at $123.48, according to data from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Image: Photo via Shutterstock

Movers

DELL

What's Going On With Dell Shares Wednesday?

Piper Sandler analyst Harsh Kumar maintains Analog Devices (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADI#NASDAQ">ADI</a>) with a Neutral and lowers the price target from $235 to $220.

Piper Sandler Maintains Neutral on Analog Devices, Lowers Price Target to $220

Flora Growth Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLGC#NASDAQ">FLGC</a>) confirmed Tuesday it renewed its sales orders for the Czech Republic and Slovakia through Just Brands UK&#8217;s customer Mirfa s.r.o.
Flora's four-year partnership with Mirfa is valued at a total demand of approximately $500,000 annually. The Florida-based cannabis operator has been supplying Mirfa with JustCBD branded products, including gummies, tinctures and oils.
&#8220;Our long-standing relationships in Europe are a testament to the strength of collaboration and mutual trust," said Clifford Starke, chairman and chief executive officer. "Over the past four years, this partnership has been a part of our European strategy, allowing us to bring premium products to customers in the Czech Republic and Slovakia. We are proud of the value this relationship continues to deliver, both in terms of revenue and brand recognition.&#8221;
The collaboration has established Flora as a supplier in the Czech and Slovakian markets, utilizing its product innovation and compliance expertise alongside Just Brands UK&#8217;s distribution network to deliver products to consumers.
The Czech Republic and Slovakia are among Europe&#8217;s emerging cannabis markets, with increasing consumer acceptance and regulatory progress driving growth opportunities for innovative companies. According to Statista, the Czech CBD market reached $34 million in 2024.
Mirfa is a Czech company specializing in CBD-infused products designed to enhance the well-being of both humans and pets. Its offerings include CBD gummies aimed at improving sleep, reducing stress and alleviating pain, as well as CBD treats formulated to promote calmness and comfort in dogs.
Read Also: <a href="https://www.benzinga.com/news/earnings/24/11/42009295/flora-growth-quarterly-revenue-falls-28-yoy-encouraged-by-president-elect-trump-and-the-potential-of-cannabis-reform">Flora Growth Quarterly Revenue Falls 28% YoY As Expenses Rise</a>
Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter <a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. If you're serious about the business, you can't afford to miss out.
<h2 class="wp-block-heading">Flora Growth And International Markets</h2>
Renewed sales orders with Mirfa come on the heels of the company's <a href="https://www.benzinga.com/markets/cannabis/24/11/41720393/flora-growth-inks-medical-marijuana-supply-agreement-with-curaleaf">medical marijuana supply agreement</a> with Curaleaf Holdings (OTCQX:<a class="ticker" href="https://www.benzinga.com/stock/CURLF#OTCQX">CURLF</a>)&#8217;s subsidiary Northern Green Canada, Inc. Under the agreement, Northern Green will supply Flora with medicinal cannabis products that Flora will distribute in the German market.
In October, Flora also signed a <a href="https://www.benzinga.com/markets/cannabis/24/10/41332773/flora-growth-teams-up-with-cannabis-giant-canopy-to-enter-94m-australian-medical-marijuana-marke">distribution agreement</a> with Canopy Growth Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGC#NASDAQ">CGC</a>) for the distribution of Canopy's Storz &amp; Bickel medical line of vaporizers in Australia. Flora&#8217;s subsidiary Australian Vaporizers will be in charge of distribution.
<h2 class="wp-block-heading">Price Action</h2>
Flora Growth shares closed Tuesday market session 2.65% higher at $1.55 per share.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/11/42204210/why-youtubes-high-science-is-a-must-watch-for-cannabis-enthusiasts">YouTube&#8217;s High Science Is A Must-Watch For Cannabis Enthusiasts</a></li>
</ul>
Photo: Courtesy of Michele Ursi via Shutterstock

CURALEAF HLDGS INC by Curaleaf Hldgs Inc.

CURLF

FLGC

Flora Growth Taps Europe's CBD Boom With $500K Czech-Slovak Partnership Renewal

Dr. Robert Murphy, the chief economist at Infineo, shared his thoughts on the evolution of blockchain in life insurance and the broader financial landscape during the <a href="https://www.benzinga.com/fintech-awards">Benzinga Fintech Awards,</a> where his company was recognized as Best Insurtech Company. 
Dr. Murphy highlighted Infineo's efforts to digitize the life insurance industry and how blockchain technology could reshape it by addressing traditional inefficiencies and enabling greater transparency.
<h4 class="wp-block-heading">Blockchain's Role in Life Insurance</h4>
At the conference, Dr. Murphy outlined Infineo&#8217;s groundbreaking work, which allows policyholders to tokenize the cash value of their life insurance policies on the blockchain.
See Also: <a href="https://www.benzinga.com/24/11/42218282/institutions-are-ready-to-play-how-blockchain-is-gaining-traction-in-traditional-finance">&#8216;Institutions Are Ready To Play&#8217;: How Blockchain Is Gaining Traction In Traditional Finance</a>
"What we're doing is allowing people to put the cash value of their life insurance policies on the blockchain, and they can mint stablecoins against it," he explained. This approach unlocks liquidity for policyholders while making life insurance a more accessible asset class for investors through fractionalized tokens.
Dr. Murphy also emphasized blockchain&#8217;s ability to address a longstanding issue in finance—opacity. "The financial sector right now is very opaque. Investors don't know what they're getting," he said. He compared the 2008 financial crisis, adding, "The mortgage-backed securities blowing up&#8230;part of the problem was nobody knew what was in these things. Now, with blockchain smart contracts, everybody knows exactly what they're buying."
<h4 class="wp-block-heading">Optimism for Regulatory Certainty</h4>
Another focal point of the discussion was the industry&#8217;s anticipation of regulatory clarity following the recent election. "Everybody, I think, is relieved to know that there's just going to be regulatory certainty," Dr. Murphy said. 
He noted that companies are not seeking special treatment but simply want a clear rulebook to continue building and innovating. "The best people will win, and the best companies will rise to the top," he added, underscoring the industry&#8217;s focus on competition and advancement.
<h4 class="wp-block-heading">The Future of Digital Assets and Blockchain</h4>
Looking ahead, Dr. Murphy predicted the continued integration of real-world assets onto the blockchain. "More and more real-world assets will be put on the blockchain," he stated. As transparency increases and familiarity with digital assets grows, he anticipates blockchain will become a standard feature of financial transactions rather than an emerging innovation.
Infineo's recognition at the Benzinga Fintech Awards highlights its leadership in modernizing the life insurance industry through blockchain. By combining regulatory clarity with cutting-edge technology, the company is driving an era of increased transparency and accessibility in financial markets.
Now Read:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42216782/long-term-bitcoin-holders-lock-in-202-billion-in-daily-realized-profits-setting-a-new-record">Long-Term Bitcoin Holders Locking In $2.02 Billion In Daily Realized Profits, Setting A New Record</a></li>
</ul>
Mohamed Hassan from Pixabay

Fintech news covering the emerging Financial Technology services sector

Fintech

Events

Interview

$3 Trillion Opportunity: Infineo Chief Economist Discusses Blockchain And The Future Of Life Insurance

Piper Sandler analyst Kashy Harrison maintains Fluence Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLNC#NASDAQ">FLNC</a>) with a Neutral and raises the price target from $18 to $20.

FLNC

Piper Sandler Maintains Neutral on Fluence Energy, Raises Price Target to $20

<a href="https://www.fda.gov/media/161640/download">https://www.fda.gov/media/161640/download</a>
&nbsp;
WARNING: HEMATOLOGIC MALIGNANCY Hematologic malignancy, including life-threatening cases of myelodysplastic syndrome, has occurred in patients treated with SKYSONA. Patients have been diagnosed between 14 months and 7.5 years after SKYSONA administration, and the cancers appear to be the result of the SKYSONA lentiviral vector, Lenti-D, integration in proto-oncogenes. Monitor patients closely for evidence of malignancy through complete blood counts at least every 6 months and through assessments for evidence for clonal expansion or predominance at least twice in the first year and annually thereafter; consider bone marrow evaluations as clinically indicated [see Warnings and Precautions (5.1)].

Biotech

BLUE

FDA Investigating Serious Risk Of Hematologic Malignancy Following Skysona (Elivaldogene Autotemcel)

Piper Sandler analyst Edward Tenthoff maintains Arrowhead Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARWR#NASDAQ">ARWR</a>) with a Overweight and lowers the price target from $62 to $45.

ARWR

Piper Sandler Maintains Overweight on Arrowhead Pharma, Lowers Price Target to $45

Floki has rallied 73% in the past mont, with market observers anticipating the uptrend to continue off the back of improving sentiment and <a href="https://www.benzinga.com/money/floki-price-prediction">bullish technical indicators</a>.
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Price&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</td>
<td>Market Cap</td>
<td>24-Hour Trend</td>
<td>7-Day Trend</td>
</tr>
<tr>
<td>Floki (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">FLOKI</a>)</td>
<td>&nbsp;$0.0002272</td>
<td>$2.2 Billion</td>
<td>&nbsp;+7.8%</td>
<td>&nbsp;-5.1%</td>
</tr>
<tr>
<td>Bonk (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">BONK</a>)</td>
<td>&nbsp;$0.00004434&nbsp;&nbsp;</td>
<td>$3.3 Billion</td>
<td>&nbsp;+6.2%</td>
<td>&nbsp;-17.4%</td>
</tr>
<tr>
<td>Dogwifhat (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">WIF</a>)</td>
<td>&nbsp;$3.14</td>
<td>$3.14 Billion</td>
<td>&nbsp;+5.5%</td>
<td>&nbsp;-2.9%</td>
</tr>
</tbody>
</table>
</figure>
Trader Notes: Crypto trader Master Kenobi noted in a <a href="https://x.com/btc_MasterPlan/status/1861546426875916659">post</a> on X on Wednesday that Floki's rally was delayed by three weeks, originally expected by Oct. 21. 
He attributes this delay to broader market reactions following the U.S. elections.
He anticipates a continuation of the uptrend, which could result in a significant &#8220;pump&#8221; around Feb. 10 in a conservative scenario. 
In a more optimistic scenario, this could also happen in mid-December, thanks to the following catalysts:
<ol start="1">
<li>Bitcoin Dominance: Expected to persist for two more weeks before easing, creating opportunities for altcoins like Floki.</li>
<li>Market Signals: Positive movements in assets like Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>) and Binance Coin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/bnb/usd">BNB</a>) point to a potential pump by late 2025.</li>
</ol>
Influencer InvestingHaven suggests that Floki has bounced from its dip, signaling a bullish breakout. 
However, he warns that the next major hurdle is surpassing its previous all-time high.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><a href="https://twitter.com/search?q=%24FLOKI&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$FLOKI</a>&#39;s consolidation phase triggered a bullish reversal, reaching our 2024 target after bouncing from the &quot;Buy the Dip&quot; level. The next major challenge for <a href="https://twitter.com/hashtag/FLOKI?src=hash&amp;ref_src=twsrc%5Etfw">#FLOKI</a> lies in testing its all-time high (ATH). <a href="https://t.co/HeyNucZVd8">pic.twitter.com/HeyNucZVd8</a>
&mdash; InvestingHaven (@InvestingHaven) <a href="https://twitter.com/InvestingHaven/status/1861373838648582544?ref_src=twsrc%5Etfw">November 26, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Community News: Coinbase Assets <a href="https://x.com/CoinbaseAssets/status/1861145726618661333">announced</a> Floki becoming available for trading for residents in Germany. Users can now buy, sell, convert, send, receive, or store Floki through Coinbase, broadening the coin's accessibility.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/movers/24/11/42102769/floki-beats-dogecoin-shiba-inu-with-double-digit-gains-after-coinbase-listing-announcement">Floki Beats Dogecoin, Shiba Inu With Double-Digit Gains After Coinbase Listing Announcement</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Comments

Bitwise Bitcoin ETF Common Shares of Beneficial Interest

Actualités

Dernières nouvelles pour Bitwise Bitcoin ETF Common Shares of Beneficial Interest (ARCA:BITB)

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL